Skip to main content
Year archive

Xbrane Biopharma — 2026 filings

All 16 regulatory filings released by Xbrane Biopharma (XBRANE) in 2026, sourced directly from the official regulator.

16 Filings
2026 Period
2026 filings (16)
Filing Released Lang
Kommuniké från årsstämma i Xbrane Biopharma AB
Regulatory Filings
2026-05-05 English
Announcement from the annual general meeting in Xbrane Biopharma AB
Regulatory Filings
2026-05-05 English
Quarterly Report 2026
Quarterly Report
2026-05-05 English
Valuation expert Venture Valuation provides external valuation of Xdivane program
Regulatory Filings
2026-05-05 English
Värderingsexperten Venture Valuation tillhandahåller extern värdering av Xdivane-programmet
Regulatory Filings
2026-05-05 English
Xbrane and its partner Intas agree on revised financing arrangement for Xbrane’s Xdivane development activities
Regulatory Filings
2026-05-05 English
Xbrane och dess partner Intas enas om ett reviderat finansieringsarrangemang för Xbranes Xdivane-utvecklingsaktiviteter
Regulatory Filings
2026-05-05 English
XBRANE SUBMITS RANIBIZUMAB BIOSIMILAR CANDIDATE TO FDA
Regulatory Filings
2026-04-30 English
XBRANE LÄMNAR IN BLA FÖR RANIBIZUMAB BIOSIMILAR KANDIDAT TILL FDA
Regulatory Filings
2026-04-30 Swedish
Xbrane uppdaterar kring tidslinjen för återinlämning av ansökan av marknadsgodkännande i USA
Regulatory Filings
2026-03-31 Swedish
Xbrane provides an update on the timeline for resubmission of the market authorization application in the United States
Regulatory Filings
2026-03-31 English
Annual Report (ESEF) 2025
Annual Report (ESEF) FY 2025
2026-03-31 Swedish
KALLELSE TILL ÅRSSTÄMMA I XBRANE BIOPHARMA AB
Proxy Solicitation & Information Statement
2026-03-31 Swedish
NOTICE OF ANNUAL GENERAL MEETING IN XBRANE BIOPHARMA AB
Proxy Solicitation & Information Statement
2026-03-31 English
Interim / Quarterly Report 2025
Interim / Quarterly Report FY 2025
2026-02-20 Swedish
Interim / Quarterly Report 2025
Interim / Quarterly Report Q4 2025
2026-02-20 English